Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade) [Seeking Alpha]
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Seeking Alpha
The increased rate of early deaths in the CARTITUDE-4 trial could reduce the use of Carvykti in later lines of multiple myeloma. Carved out data in earlier lines of multiple myeloma point to much lower potential in earlier lines of multiple myeloma. With these new data in mind, Legend Biotech no longer appears like an attractive investment opportunity. Looking for a helping hand in the market? Members of Growth Stock Forum get exclusive ideas and guidance to navigate any climate. Learn More » When I first saw the AdCom briefing documents for Legend Biotech's NASDAQ: LEGN ) and Johnson & Johnson's JNJ ) Carvykti, I thought the stock would surely plunge. But that is not what happened and there was only a slight dip followed by a recovery to recent highs. I was previously bullish on Legend and Carvykti's growth prospects and the stock is up approximately 40% since my first article in October 2022 and down slightly since my last update in August 2023 where I highlighted Carvykt
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech Co. (NASDAQ: LEGN) had its price target raised by analysts at Royal Bank of Canada from $85.00 to $86.00. They now have an "outperform" rating on the stock.MarketBeat
- Legend Biotech GAAP EPS of -$0.16 beats by $0.02, revenue of $93.99M misses by $47.37M [Seeking Alpha]Seeking Alpha
- Legend Biotech Reports First Quarter 2024 Results and Recent HighlightsBusiness Wire
- Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.MarketBeat
- Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.MarketBeat
LEGN
Earnings
- 5/13/24 - Beat
LEGN
Sec Filings
- 5/13/24 - Form 6-K
- 4/22/24 - Form 6-K
- 4/16/24 - Form 6-K
- LEGN's page on the SEC website